Centers for Disease Control and Prevention Center for Preparedness and Response



2020-2021 Influenza Vaccination Recommendations and Clinical Guidance during the COVID-19 Pandemic

Clinician Outreach and Communication Activity (COCA) Webinar

Thursday, August 20, 2020

Continuing Education

All continuing education for COCA Calls are issued online through the CDC Training & Continuing Education Online system at <u>https://tceols.cdc.gov/</u>

Those who participate in today's COCA Call and wish to receive continuing education please complete the online evaluation by **September 21, 2020**, with the course code **WC2922-082020**. The access code is **COCA082020**. Those who will participate in the on-demand activity and wish to receive continuing education should complete the online evaluation between **September 22, 2020**, and **September 22, 2022**, and use course code **WD2922-082020**. The access code is **COCA082020**.

Continuing education certificates can be printed immediately upon completion of your online evaluation. A cumulative transcript of all CDC/ATSDR CEs obtained through the CDC Training & Continuing Education Online System will be maintained for each user.

Continuing Education Disclaimer

- In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.
- Planners have reviewed content to ensure there is no bias.
- Content will not include any discussion of the unlabeled use of a product or a product under investigational use, except Dr. Lisa Grohskopf's discussion on the recommendations of the Advisory Committee on Immunization Practices (ACIP), where Dr. Grohskopf is the CDC Lead for the Influenza Work Group. The ACIP recommendations for persons with a history of severe allergic reaction to egg is a labeled contraindication for receipt of most influenza vaccines. However, ACIP recommends that persons with egg allergy of any severity should receive any licensed influenza vaccine appropriate for their age and health status. This will be explained during the presentation.
- CDC did not accept commercial support for this continuing education activity.

Objectives

At the conclusion of the session, the participant will be able to accomplish the following—

- Summarize updates to ACIP recommendations for the 2020-21 influenza vaccination season.
- Discuss the Standards for Adult Immunization Practice and general vaccination guidance during the COVID-19 pandemic.
- Describe flu vaccination planning and guidance for large vaccination clinics held in satellite, temporary, or off-site locations.

To Ask a Question

- All participants joining us today are in listen-only mode.
- Using the Webinar System
 - Click the "Q&A" button.
 - Type your question in the "Q&A" box.
 - Submit your question.
- Click the "CC" button in Zoom to enable closed captioning.
 - "CC" button is located either on the top or bottom of your screen.
- The video recording of this COCA Call will be posted at <u>https://emergency.cdc.gov/coca/calls/2020/callinfo_082020.asp</u> and available to view on-demand a few hours after the call ends.
- If you are a patient, please refer your questions to your healthcare provider.
- For media questions, please contact CDC Media Relations at 404-639-3286, or send an email to media@cdc.gov.

Today's Presenters

Lisa Grohskopf, MD, MPH, CAPT, USPHS
 Medical Officer, Influenza ACIP Lead
 Epidemiology and Prevention Branch, Influenza Division
 National Center for Immunization and Respiratory Diseases
 Centers for Disease Control and Prevention

Tara Jatlaoui, MD, MPH, FACOG, LCDR, USPHS
Co-Lead, Influenza Response Team
Vaccine Planning Unit, Immunization Services Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Amy Parker Fiebelkorn, MSN, MPH, CAPT, USPHS Co-Lead, Influenza Response Team Vaccine Planning Unit, Immunization Services Division National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention **Centers for Disease Control and Prevention** National Center for Immunization and Respiratory Diseases



ACIP Influenza Vaccination Updates for the 2020–21 Season

Lisa Grohskopf, MD, MPH Influenza Division, NCIRD, CDC

Clinician Outreach and Communication Activity (COCA) Call August 20, 2020

Abbreviations

- IIVInactivated Influenza VaccineccIIV4Cell-culture-based inactivated influenza vaccineaIIV3, aIIV4Adjuvanted inactivated influenza vaccineHD-IIV4High-dose inactivated influenza vaccine
- **RIV4** Recombinant influenza vaccine
- LAIV4 Live, attenuated influenza vaccine

Numbers indicate the number of influenza virus antigens:

3 for trivalent: an A(H1N1), an A(H3N2), and one B (from one lineage) 4 for quadrivalent: an A(H1N1), an A(H3N2), and two Bs (one from each lineage)

2020–21 ACIP Influenza Statement

Core recommendation (unchanged):

 Annual influenza vaccination is recommended for all persons aged 6 months and older who do not have contraindications.

2020–21 ACIP Influenza Statement

- Primary updates:
 - U.S. influenza vaccine viral composition
 - Addition of two recently licensed vaccines
 - Fluzone High-Dose Quadrivalent
 - Fluad Quadrivalent
- Updates in:
 - Live, attenuated influenza vaccine and influenza antivirals
 - Discussion and Table of contraindications/precautions
 - Recommendations for persons with severe egg allergy

2020–21 Influenza Vaccine Composition

- Egg-based IIVs and LAIV4:
 - An A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-<u>like</u> virus;
 - An A/Hong Kong/2671/2019 (H3N2)-<u>like</u> virus;
 - A B/Washington/02/2019 (Victoria lineage)-<u>like</u> virus; and
 - (IIV4s and LAIV4) a B/Phuket/3073/2013 (Yamagata lineage)-<u>like</u> virus.
- Cell-culture-based IIV4 and RIV4:
 - An A/Hawaii/70/2019 (H1N1)pdm09-<u>like</u> virus;
 - An A/Hong Kong/45/2019 (H3N2)-<u>like</u> virus;
 - A B/Washington/02/2019 (Victoria lineage)-<u>like</u> virus; and
 - A B/Phuket/3073/2013 (Yamagata lineage)-<u>like</u> virus.

U.S.-Licensed Influenza Vaccines Expected for 2020–21

Vaccine type	6 through 23 mos	2 through 3 yrs	4 through 17 yrs	18 through 49 yrs	50 through 64 yrs	≥65 yrs
IIV4s (egg)	Afluria Quadriva Fluarix Quadriva FluLaval Quadriv Fluzone Quadriv	lent lent valent alent				
ccIIV4 (cell)		Flucelvax Quadrivalent				
RIV4 (recombinant)				Flublok Quadrivalent		
Adjuvanted allV3 (egg)						Fluad
Adjuvanted allV4 (egg)						Fluad Quadrivalent NEW
High-dose HD-IIV4 (egg)						Fluzone High-Dose Quadrivalent
LAIV4 (egg)		FluMist Quadriv	alent			

- No influenza vaccines are licensed for children under 6 months of age.
- For children 6 through 35 months of age, volume per dose is different than for older persons—refer to PI for dose volumes.
- For many people, there is more than one appropriate vaccine.
- ACIP expresses no preference for any one influenza vaccine over another where more than one is appropriate.
- All are intramuscular except for LAIV4 (intranasal).
- LAIV4 should not be used for some groups, including pregnant women and certain other populations (see ACIP statement).

New Influenza Vaccine Licensures

November 2019:

- Fluzone High-Dose Quadrivalent (Sanofi Pasteur)
 - Licensed for ≥65 years
 - 60 mcg hemagglutinin per vaccine virus in a 0.7 mL dose (240 mcg total)
 - Will replace previous trivalent Fluzone High-Dose for 2020–21

February 2020:

- Fluad Quadrivalent (Seqirus)
 - Licensed for ≥65 years
 - Contains MF59 adjuvant
 - Will be available in addition to previous trivalent Fluad

Influenza Antivirals and LAIV4

- Previous guidance--antivirals from 48 hours before to 2 weeks after administration of LAIV4 may interfere with vaccine
- Newer antivirals peramivir and baloxavir have longer half-lives than oseltamivir and zanamivir.
- Insufficient data available on use of LAIV4 in setting of antiviral use
- Based on half-lives and assuming normal clearance, reasonable to assume interference possible if antivirals are administered within these intervals:

Antiviral	Interval
Oseltamivir and Zanamivir	48 hours before to 2 weeks after LAIV4
Peramivir	5 days before to 2 weeks after LAIV4
Baloxavir	17 days before to 2 weeks after LAIV4

LAIV4 Use in Settings of Asplenia, Cochlear Implant, and Active Cranial Cerebrospinal Fluid (CSF) Leak

- Anatomic and functional asplenia, cochlear implant, and CSF leak discussed last season in section on immunocompromised hosts
- Insufficient data for use in these populations
- Alternative vaccines are available (IIVs, RIV4).
- Added to list of contraindications for LAIV4 in Table 2
 - For cochlear implant, footnote suggests consultation with expert regarding risk for persistent CSF leak, if an injectable vaccine cannot be used.

Vaccination of Persons with Egg Allergy

- Language concerning persons with a history of severe allergic reaction to egg (having had any symptom other than hives after egg ingestion) updated for two egg-free vaccines:
 - Cell-culture-based inactivated vaccine (ccllV4)
 - Recombinant influenza vaccine (RIV4).
- For these individuals, if a vaccine other than ccllV4 or RIV4 is selected, it should be administered in an inpatient or outpatient medical setting, supervised by a health care provider who is able to recognize and manage severe allergic reactions.

Influenza Vaccines for Children 6 through 35 mos

- Four IIV4s licensed for this age group
- Dose volumes for this age group differ:
 - FluLaval Quadrivalent (IIV4, GSK)
 - Fluarix Quadrivalent (IIV4, GSK)
 - *Afluria Quadrivalent* (IIV4, Seqirus)
 - Fluzone Quadrivalent (IIV4, Sanofi Pasteur)

- 0.5 mL 0.5 mL 0.25 mL 0.25 mL *or* 0.5 mL
- Fluzone Quadrivalent 0.25 mL prefilled syringes will not be available for 2020–21

PRELIMINARY Adjusted vaccine effectiveness against medically attended influenza, US Flu VE Network, 2019–20 (as of June 9, 2020)



*Multivariable logistic regression models adjusted for site, age, sex, race/ethnicity, self-rated general health status, interval from onset to enrollment, and calendar time.

Preliminary results presented at ACIP, June 24, 2020. For more information on the US Flu VE Network: https://www.cdc.gov/flu/vaccines-work/us-flu-ve-network.htm

Estimated Benefits of Influenza Vaccination, 2018–19

- Estimated vaccine effectiveness for 2018-19:
 - 29% overall
- Estimated vaccination coverage:
 - 49% overall
- Estimated burden averted through vaccination
 - 4.4 million illnesses
 - 58,000 hospitalizations
 - 3,500 deaths

the benefits of flu vaccination 2018-2019

Approximately 49% of the U.S. population chose to get a flu vaccine during the 2018-2019 flu season, and this prevented an estimated:



https://www.cdc.gov/flu/resource-center/freeresources/graphics/flu-vaccine-protected-infographic.htm

Southern Hemisphere Influenza Activity

- Southern Hemisphere influenza activity has been reported at much lower rates than is typical.
- Fewer countries are reporting data, and fewer viruses are being detected in general.
- Influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B/Victoria viruses have co-circulated.
- Social distancing and other preventive measures to reduce spread of SARS-CoV-2 may also have helped reduce spread of influenza viruses.
- The COVID-19 pandemic also has influenced health-seeking behaviors and testing priorities and capacities, making interpretation challenging.

Upcoming 2020–21 U.S. Influenza Season

- It is unclear what impact the ongoing COVID-19 pandemic will have on the upcoming influenza season in the U.S.
 - There may be less influenza than usual because of social distancing and other measures to reduce COVID-19.
 - Influenza viruses and SARS-CoV-2 may co-circulate.
 - People may be co-infected with influenza and SARS-CoV-2.
- Presence of SARS-CoV-2 and influenza at the same time could place tremendous burden on the health care system and result in many illnesses, hospitalizations, and deaths.



Standards for Adult Immunization and Vaccination Guidance during the COVID-19 Pandemic

LCDR Tara C. Jatlaoui, MD, MPH

Vaccine Planning Unit

Influenza Response Team Co-Lead

COCA Call August 20, 2020

Standards for Adult Immunization Practice

- All health care providers, including those who do not provide vaccination services, have role in ensuring adult patients up to date on vaccines
- Call to action for adult health care providers to:
 - ASSESS vaccination status of all patients at every clinical encounter.
 - Strongly **RECOMMEND** vaccines that patients need.
 - ADMINISTER needed vaccines or **REFER** to a vaccination provider.
 - **DOCUMENT** vaccines received by patients in state vaccine registries.

Standards for Adult Immunization Practice

- Professional health-care-related organizations, associations, or systems
 - Provide immunization education and training of members, including trainees.
 - Provide resources to **implement protocols** to routinely assess, vaccinate, or refer.
 - Encourage members to be up to date on their own immunizations.
 - Partner with other immunization stakeholders to educate the public.
 - Seek out **collaboration** opportunities with other immunization stakeholders.
 - Collect and **share best practices** for immunization.
 - Advocate policies that support adult immunization standards.
 - Insurers/payers/entities assure their network is adequate to provide timely immunization access and augment with additional vaccination providers if necessary.

Strategies to Promote Adult Immunization



Administrative

- Immunization Champion
- Management support
- Effective policy
- Provider assessment and feedback



Programmatic

- On site vaccination
- Reduction in out-ofpocket costs
- Standing orders
- Reminder-recall
- Immunization information system

- Communication
 - Patient values and needs
 - Provider recommendations

www.thecommunityguide.org/vaccines/index.html

Making a Strong Vaccine Recommendation: #HowIRecommend Videos



www.cdc.gov/vaccines/howirecommend/adult-vacc-videos.html

Medscape Module: How to Give a Strong Recommendation to Adult Patients Who Require Vaccination

- Case Presentations/Videos
- Older Adult
 - -Zoster
 - PCV13
- Adult with Diabetes
 - Hepatitis B
 - Influenza
- Pregnant Woman
 - Tdap
 - Influenza



Vaccination during the COVID Pandemic

CDC Interim Guidance for Immunization Services During COVID-19 Pandemic

- Vaccination is an essential medical service for all children and adolescents, ideally in the medical home.
- Administer all due or overdue vaccines according to routine immunization schedule during the same visit.
- Implement strategies to catch all patients up on vaccines.
 - Start with newborns, infants, and children up to age 24 months, young children, and extending through adolescence
- Includes guidance for the safe delivery of vaccines (e.g., use of personal protective equipment, physical distancing)



Routine Immunization Services Remain Critical

- Routine vaccination prevents disease in the individual, the family, and the community.
- Routine vaccination also prevents illnesses that lead to unnecessary medical visits and hospitalizations, further straining the healthcare system.
- Getting a flu vaccine is always the most important thing we can do to help protect ourselves, our loved ones and our community from flu, including reducing the risk of serious outcomes that can lead to hospitalization and death.

Decreasing Vaccination Coverage Means It Is Particularly Important to:

- Assess the vaccination status of all patients to avoid missed opportunities and ensure timely vaccination catch-up.
- Administer all vaccines due or overdue according to the recommended <u>CDC</u> <u>immunization schedules</u> during a visit.





0

https://www.cdc.gov/vaccines/pandemic-guidance/index.html

Vaccination Documentation

Because patients may be receiving vaccines outside their medical home, it is critical all vaccines are documented for accurate and timely information on patient vaccination status.



Persons with Suspected or Confirmed COVID-19

 Routine vaccination should be deferred for persons with suspected or confirmed COVID-19, regardless of symptoms.



https://www.cdc.gov/vaccines/pandemic-guidance/index.html

Implement Enhanced Infection Control Measures

- Screen patients for COVID-19 symptoms before and during the visit.
- Physical distance (at least 6 feet apart, where possible)
- Limit and monitor facility points of entry and install barriers to limit physical contact with patients at triage.
- Respiratory hygiene (facemasks for staff and face coverings for patients over 2 years of age, if tolerated) and cough etiquette
- Hand hygiene (including at least 60% alcohol hand sanitizer for patients)
- Enhanced surface decontamination

Refer to guidance to prevent the spread of COVID-19 in <u>health care settings</u>, including <u>outpatient and ambulatory care settings</u>.

Use Personal Protection Equipment

Face mask

 Recommended: All health care providers (N95 masks not recommended)

Eye protection



- Recommended: Areas of moderate/substantial community transmission
- Optional: Areas of minimal/no community transmission



Gloves

- Recommended: intranasal or oral vaccines
- Optional: intramuscular or subcutaneous vaccines

Ensure Physical Distancing during Vaccination Visits

Separate sick from well patients



- Schedule well and sick visits at different times of the day.
- Place sick visits in different areas of the facility or different locations.

Ensure physical distancing measures



- At least 6 feet during all aspects of visit: check-in, checkout, screening procedures, postvaccination monitoring
- Use strategies such as physical barriers, signs, ropes, floor markings.

Reduce crowding in waiting room



 Ask patients to wait outside (e.g., in their vehicles) until called in.

Vaccination Guidance Is Continuously Being Reviewed and Updated

- Visit <u>https://www.cdc.gov/vaccines/pandemic-guidance/index.html</u> for the most recent guidance.
- Sign up to be notified when information on the web page changes.





Flu Vaccination Planning and Guidance for Vaccination Clinics in Satellite, Temporary, or Off-Site Locations

CAPT Amy Parker Fiebelkorn, MSN, MPH Influenza Response Team Co-Lead Vaccine Planning Unit



Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

Flu Vaccination Planning for 2020-21

Increasing Seasonal Influenza Vaccination Coverage to Decrease Health Care Utilization, 2020-21

- Expect SARS-CoV-2 to continue to circulate in the fall.
- Increasing flu vaccination coverage will reduce stress on the health care system.
 - Decrease doctor visits and hospitalizations.
 - Reduce influenza diagnostic testing.
- Focus on adults at higher risk from COVID-19.
 - Staff and residents of long-term care facilities
 - -Adults with underlying illnesses
 - -African-Americans and Hispanics
 - Adults who are part of critical infrastructure



Influenza Vaccination Planning for 2020-2021 Season

- Maximize available vaccine supply.
 - Expect >190M doses for U.S. market.
- Operational considerations
 - Outreach to those at higher risk
 - Planning for need to physical distance
 - Extending influenza vaccination season (September through December or later)
- Enhance communication.
 - Align with COVID-19 messaging.
 - Messaging for high-risk individuals

Influenza Vaccine Doses Distributed By Season, 2008-09 to 2019-20, and Projected, 2020-21



Barriers to Flu Vaccination during the Pandemic

- There might be fewer worksite vaccination clinics (~16% of adults receive flu vaccination at the workplace).
- People might not feel safe going into clinics or pharmacy settings.
- In-person clinic visits might be cancelled or moved to telehealth.
- Concerns about safety of COVID-19 vaccine could translate to (more) questions about safety of flu vaccine.
- COVID-19-related unemployment might impact ability to afford flu vaccination.
- Working parents have limited free time to focus on staying up to date on vaccinations because of work/home school/child care responsibilities.
- People might not think they need a flu vaccination this year because they are physically distancing.

https://www.cdc.gov/flu/fluvaxview/place-vaccination-2014-15.htm

Activities Critical to Successful Flu Vaccination Season

- Coordinated messages from CDC, providers, health departments, and medical professional societies on the importance of flu vaccination (and where patients can receive flu vaccination)
- Protocols in place to ensure patients can be safely vaccinated
- Creative approaches to address access/disparity issues and common misperceptions about flu vaccination
- Information on Medicaid, Vaccines for Children, insurance subsidies, or payment options for patients who have recently lost insurance coverage or are experiencing economic hardship
- Vaccination efforts continue for the duration of flu season.

Guidance for Vaccination Clinics in Satellite, Temporary, or Off-Site Locations

Guidance for Vaccination Clinics Held in Satellite, **Temporary, or Off-site locations**



Guidance during the COVID-19 pandemic

Planning for a satellite, temporary, or off-site vaccination clinic requires additional considerations during the COVID-19 pandemic, including physical distancing, personal protective equipment (PPE), and enhanced sanitation efforts. These additional considerations are called out in boxes throughout this guidance. However, because COVID-19 guidance is evolving, regularly check infection control guidance for healthcare professionals about coronavirus (COVID-19) for updated information. Consider signing up for the email updates on the website to stay informed of any changes.

83 **Planning Activities**



Pre-Clinic Activities



Post-Clinic Activities

Planners are encouraged to use

- Resources for hosting an off-site vaccination clinic
- The Checklist of Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations,
- Which outlines CDC guidelines and best practices essential for patient safety and vaccine effectiveness, including guidance for vaccine shipment, transport, storage, handling, preparation, administration, and documentation at temporary clinics.

https://www.cdc.gov/vaccines/hcp/admin/mass-clinic-activities/index.html

Checklist of Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off-site Locations

	E SHIPI	<u>CLUTU (Prease complete each ritem before the clunic starts.)</u> Vi Vacine was shipped directly to the facility/clinic site, where adequate storage is available. (<i>Direct shipment is preferred for cold chain inte</i> Vacine was shipped directly to the facility/clinic site, where adequate storage is available. (<i>Direct shipment is preferred for cold chain inte</i> Vacines were transported using a partable vaccine refrigerator or qualified centainer and pack-out designed to transport outcome the temperature range recommended by the manufacturum (<i>a</i> , between 2–8° Calsia or 36–6° Fahrenholt for ALL refrigerated vaccines the temperature range recommended by the manufacturum (<i>a</i> , between 2–8° Calsia or 36–6° Fahrenholt to ALL refrigerated vaccines the temperature range recommended by the manufacturum (<i>a</i> , between 2–8° Calsia or 36–6° Fahrenholt to FALL refrigerated vaccines the temperature range recommended by the manufacturum (<i>a</i> , between 2–8° Calsia or 36–6° Fahrenholt to FALL refrigerated vaccines the temperature range recommended by the manufacturum (<i>a</i> , between 2–8° Calsia or 36–6° Fahrenholt to FALL refrigerated vaccines the temperature range recommended by the manufacturum (<i>a</i> , between 2–8° Calsia or 36–6° Fahrenholt to FALL refrigerated vaccines the temperature range recommended by the manufacturum (<i>a</i> , between 2–8° Calsia or 36–6° Fahrenholt to FALL refrigerated vaccines the temperature range recommended by the manufacture (<i>a</i> , between 2–8° Calsia or 36–6° Fahrenholt to FALL refrigerated vaccines the temperature range recommended by the manufacture (<i>a</i> , between 2–8° Calsia or 36–6° Fahrenholt to FALL refrigerated vaccines the temperature range recommended by the temperature range temperature range recommended by the temperature range temper
	E SHIPI	IT Vaccine was shipped directly to the facility/clinic site, where adequate storage is available. (Direct shipment is preferred for cold chain into ORT (IF IT WAS NOT POSSIBLE TO SHIP VACCINES DIRECTLY TO THE FACILITY/CLINIC SITE) Vaccines were transported using a partable vaccine refrigerator or qualified container and pack-out designed to transport vaccines the temperature range recommended by the manufacturers (a, between 2–3° Calisus or 36–45° Fahrenhalt for ALL integrated vaccines Coles available to renear merizabane stores occore used to transport one DIT OLOFENEE. So COS Vaccine Storage and He
YES VACCINI YES	E TRAN	Vaccine was shipped directly to the facility/clinic site, where adequate storage is available. (<i>Direct shipment is preferred for cold chain inth</i> ORT (IF IT WAS NOT POSSIBLE TO SHIP VACCINES DIRECTLY TO THE FACILITY/CLINIC SITE) Vaccines were transported using a partable vaccine refrigerator or qualified centainer and pack-out designed to transport vaccines the temperature range recommended by the manufacturers (<i>a</i> , between 2–8° Colisus or 84–6° Fahrenheit for ALL refrigerated vaccines Coolens available tangeral regretance stores or coolens and to transport Deal POI ADD (2012) ESS COC 95 Vaccine Storage and H
VACCINI YES	E TRAN	Vaccine was shaped directly to the lacethycline cale, where adequals obrage is available. Unlike thermal a pertained for cold chain the Net (IF IT WAS NOT POSSIBLE TO SHIP VACCINES DIRECTLY TO THE FACILITY/OLINIC SITE) Wascines were transported using a pertained watchine refrigerator or qualified cardializer and pack-cut designed to transport vaccines the temperature range recommended by the manufacturers (a, between 2–8° Colisia or 38–46° Fahrenhott for ALL refrigerated watchine Cooliers, available at great marginalizer stores or coolier and to transport for an UTI ADTERDED SociEC Socie S
	E TRAN	ORT ((F IT WAS NOT POSSIBLE TO SHIP VACCINES DIRECTLY TO THE FACILITY/CLINIC SITE) Vaccines were transported using a partable vaccine refrigerator or qualified container and pack-out designed to transport vaccines the temperature range recommended by the manufactures (a, between 2-3° Calina or 33-45° Fahrenhalt for ALL infigeration vaccines Coolern available to ranger instruments enters or cooler used to transport food and IDI ADE TRADE. So COO's Vaccine Socie Socie Cool Vaccine Storage and He Socies and Storage and He and to transport food and IDI ADE TRADE. So COO's Vaccine Socie Socies Coo's Vaccine Storage and He Socies and Storage and He and Transport food and IDI ADE TRADE. So COO's Vaccine Socies Coo's Vaccine Storage and He Socies Advised Storage and He and Transport food and IDI ADE TRADE.
		Vaccines were transported using a partable vaccine refrigerator or qualified centainer and pack-out designed to transport vaccines the temperature range recommended by the manufactures (a, between C-8° Calsiau or 36-46° Fahrenheit for ALL refrigerated vaccines (coloris, wailable at general merghandes tensor coclear used to transport focus PMI ADC PAREA Sec ADC 59 Vaccine Storage and He
		Vaccines were transported using a portable vaccine refrigerator or qualified container and pack-out designed to transport vaccines the temperature range recommended by the manufactures (a.e. between 2-98 Cosis or 36-46 ² Fahrunehit for ALL refrigerated vaccines <u>Coolers available at general merchandise stores or coolers used to transport food are NOT ACCEPTABLE</u> . See CDC's Vaccine Storage and Ha
		Iootkit for information on qualified containers and pack-outs: www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pd
		The person transporting the vaccines confirmed that manufacturer instructions for packing configuration and proper conditioning of coolar were followed. (Your qualified container and pack-out should include packing instructions. If not, contact the company for instructions on proper packing procedures.)
		The person transporting the vaccines confirmed that all vaccines were transported in the passenger compartment of the vehicle (NOT in the vehicle trunk).
		A digital data logger with a buffered probe and a current and valid Certificate of Calibration Testing was placed directly with the vaccines a used to monitor vaccine temperature during transport.
		The amount of vaccine transported was limited to the amount needed for the workday.
VACCIN	E STOR	E AND HANDLING (UPON ARRIVAL AT FACILITY/CLINIC)
YES	NO	
		If vaccines were shipped, the shipment arrived within the appropriate time frame (according to manufacturer or distributor guidelines) and good condition.
		The vaccine shipment contained a cold chain monitor (COA), it was checked upon arrival at the facility/clinic, and there was no indicators themperature accuration (i.e., and cf-ange themperature) accuration is an apartar cold an as arrived to the monitor (COA) may not be included when vaccines are shipped directly from the manufacture). <i>Note: COMs are for one-time use and should be thin away after briege included</i> .
		Upon arrival at the facility/clinic (either by shipment or transport, vacciones were immediately unpacked and placed in proper storage equil- (a, a, portable vaccine refrigerator or qualified container and pack-out sporticity) designed and testero to maintain the mandfacture- recommended temperature namp). Follow the guidance for unpacking and storing vaccines geneilfed in CDC's Vaccine Storage and Handli Tookit: www.cc/guivaccines/pcating/tainity tainage/hos/tainage/handling-tookit.gdd.
		Upon arrival at the facility/clinic, vaccines were still within the manufacturer-recommended temperature range (i.e., between 2–8° Celsius 36–46° Fahrenheit for ALL refrigerated vaccines).
		Upon arrival at the facility/clinic, vaccines remained protected from light (per manufacturer's package insert) until ready for use at the vaccination clinic.
	•	Upon arrival at the facility/clinic, expiration dates of vaccines and any medical equipment (syringes, needles, alcohol wipes) being used we checked, and they had not expired.
CLINIC I	PREPAR	ION AND SUPPLIES
YES	NO	
		A contingency plan is in place in case vaccines need to be replaced. The plan addresses scenarios for vaccine compromised before arriva the clinic and for vaccine compromised during clinic hours.
		An emergency medical kit (including epinephrine and equipment for maintaining an airway) is at the site for the duration of the clinic.

https://www.izsummitpartners.org/content/uploads/2019/02/off-site-vaccination-clinic-checklist.pdf

Planning Activities



Leadership and Staffing



Vaccination Clinic Location and Layout



Coordinate with
 Government, Nonprofit,
 and Private Sector Partners

https://www.cdc.gov/vaccines/hcp/admin/mass-clinic-activities/planning-activities.html

Flowchart for Vaccination Clinic Layout for Walk-through Clinics

9 Eligibility Waiting Medical CLINIC Vaccination EXIT screening area area screening/ area (multiple stations) treatment area (multiple stations) (as needed) 8 0 Payment Post CLINIC **Registration**/ area vaccination ENTRANCE Q&A/form (multiple stations, i.e., waiting area completion area Medicare, private (multiple stations) insurance)

Indoor or outdoor walk-through clinics

*These activities can also be combined with activities, for example, they might be part of activity 1 or 3

Flowchart for Vaccination Clinic Layout of Curbside Clinics



https://www.cdc.gov/vaccines/hcp/admin/mass-clinic-activities/pre-clinic-activities.html

Vaccine Finder

VaccineFinder Improving Access to Vaccines

VaccineFinder helps find providers that offer seasonal flu vaccine and other

immunizations. <u>https://vaccinefinder.org</u>

- Easy-to-use website directs patients to locations with immunizations on hand.
- Saves time and resources during a seasonal outbreak or pandemic
- New in August 2020!
 - 8/3: Modernized website
 - 8/24: Updated process for providers to report supply and more accurate reporting (automated and manual ways to report)



VaccineFinder Manual Data Reporting

FinderTools Providers	Jsers Resources					
← Back to Providers						
	Add a Prov	ider: Partners Health Clinic				
Organization Details	rganization Details When are flu vaccines available?					
	Start Date	End Date				
2 Vaccine Availability	10/5/2020	₿ 04/05/2020				
Medication Availability						
Select all vaccines this location provides.						
	🗾 рт					
	Additional Data					
	Show vaccine cost	Show current supply level				
	Cost					
	\$ 10					
	Current Supply					
	High Medium	Low No supply				
	High Supply represents +2 Day n	redication supply				
	DTaP					
	Hepatitis A (Child)	^				
	Additional Data Show vaccine cost	Show current supply level				

FinderTools MW Providers Users Resources Providers MANAGE PROVIDERS 💙 Partners Health Clinic Add a Provider Import Providers (CSV Import) VaccineFinder Providers (2.463) All Providers (2.463) MedFinder Providers (1.568) Automated Upload Settings Flu Nasal Trivalent Intradermal Quadrivalent Adjuvanted PROVIDER 🕹 ADDRESS FLU START 🕕 FLU END 🕕 Flu Shot Spray Flu Shot Flu Shot Flu Shot 34 South Allison Ave O Partners Health Clinic #106 Jul 15, 2019 Mar 1, 2020 Xenia, OH 34585 107 Main St Partners Health Clinic #115 Jul 15, 2019 Mar 1, 2020 Ð Greenfield, MA 01902 755 Memorial PKY (US HWY 22) Partners Health Clinic #059 Jul 15, 2019 Mar 1, 2020 Ð Phillipsburg, NJ 08865 80 East Main St Partners Health Clinic #025 Jul 15, 2019 Mar 1, 2020 **00** O Clinton, MA 01902 107 Main St Partners Health Clinic #139 O Jul 15, 2019 Mar 1, 2020 Clinton, MA 01902 5 Cliff Road Partners Health Clinic #009 Ð Jul 15, 2019 Mar 1, 2020 Clinton, MA 01902 1 2 3 ··· 8 9 10 > 60 Show 30 ~ Go to Page 2+ day supply (High) - 1-2 day supply (Medium) - (I day supply (Low))

The Contributor Dashboard supports manual entry of projected vaccine supply estimates for providers.

Onboarding

- Enrollment process:
 - Providers enroll and review technical methodology for reporting.
 - Confirm data reporting methods:
 - Automated secure data transfer
 - Manual upload via Contributor Dashboard
 - Providers report supply estimates for vaccines they carry.
- The VaccineFinder team is available to provide technical assistance and support.
- For questions or more information, contact <u>vaccine@healthmap.org</u>.

We encourage partners to update vaccine availability more frequently this flu season. Please note: To ensure accuracy of information, sites with updates older than 2 weeks will not display on VaccineFinder.

Join Us to Learn More!

The VaccineFinder team will be hosting information and training webinars for new and existing enrolled providers:

- August 26, 2020
- August 31, 2020
- September 2, 2020

Email <u>vaccine@healthmap.org</u> for more information on joining one of these upcoming webinars!

Conclusions

Conclusions

- Strongly promote flu vaccination especially this season in the context of the pandemic—and particularly among our most vulnerable populations.
- Continue vaccinating for the duration of flu season.





Thank you

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 <u>www.cdc.gov</u>

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.



To Ask a Question

- Using the Zoom Webinar System
 - Click on the "Q&A" button.
 - Type your question in the "Q&A" box.
 - Submit your question.
- For media questions, please contact CDC Media Relations at 404-639-3286 or email <u>media@cdc.gov</u>.

Continuing Education

All continuing education for COCA Calls are issued online through the CDC Training & Continuing Education Online system at <u>https://tceols.cdc.gov/</u>

Those who participate in today's COCA Call and wish to receive continuing education please complete the online evaluation by **September 21, 2020**, with the course code **WC2922-082020**. The access code is **COCA082020**. Those who will participate in the on-demand activity and wish to receive continuing education should complete the online evaluation between **September 22, 2020**, and **September 22, 2022**, and use course code **WD2922-082020**. The access code is **COCA082020**.

Continuing education certificates can be printed immediately upon completion of your online evaluation. A cumulative transcript of all CDC/ATSDR CEs obtained through the CDC Training & Continuing Education Online System will be maintained for each user.

Today's COCA Call Will Be Available On-Demand

• When: A few hours after the live call

What: Video recording

Where: On the COCA Call webpage at https://emergency.cdc.gov/coca/calls/2020/callinfo_082020.asp

Upcoming COCA Call

- Topic: Testing and Treatment of Seasonal Influenza During the COVID-19 Pandemic
- Date: Thursday, September 17, 2020
- Time: 2:00-3:00 PM ET
- Website: <u>https://emergency.cdc.gov/coca/calls/2020</u> (further details coming soon)

COCA Products & Services

🥑 🚱 COCA Call

CDC Clinician Outreach and Communication Activity

🥑 🛞 COCA Learn



CDC Clinician Outreach and Communication Activity

S Clinical Action

CDC Clinician Outreach and Communication Activity COCA Call Announcements contain all information subscribers need to participate in COCA Calls. COCA Calls are held as needed.

Monthly newsletter that provides information on CDC training opportunities, conference and training resources, the COCA Partner Spotlight, and the Clinician Corner.

As-needed messages that provide specific, immediate action clinicians should take. Contains comprehensive CDC guidance so clinicians can easily follow recommended actions.

COCA Products & Services

🥑 🛞 COCA Digest

CDC Clinician Outreach and Communication Activity

S COCA Now



CDC Clinician Outreach and Communication Activity



Monthly newsletter providing updates on emergency preparedness and response topics, emerging public health threat literature, resources for health professionals, and additional information important during public health emergencies and disasters.

Informs clinicians of new CDC resources and guidance related to emergency preparedness and response. This email is sent as soon as possible after CDC publishes new content.

CDC's primary method of sharing information about urgent public health incidents with public information officers; federal, state, territorial, and local public health practitioners; clinicians; and public health laboratories.

Join COCA's Mailing List

- Receive information about:
 - Upcoming COCA Calls
 - Health Alert Network (HAN) messages
 - CDC emergency response activations
 - Emerging public health threats
 - Emergency preparedness and response conferences
 - Training opportunities



Clinician Outreach & Communication Activity emergency.cdc.gov/coca

emergency.cdc.gov/coca

Join Us On Facebook!





CDC Clinician Outreach and Communication Activity - COCA @CDCClinicianOutreachA ndCommunicationActivity

```
Home
About
Posts
Photos
Events
Community
```

Create a Page



Thank you for joining us today!



emergency.cdc.gov/coca